Your browser doesn't support javascript.
loading
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
Gubens, Matthew A; Burns, Matthew; Perkins, Susan M; Pedro-Salcedo, Melanie San; Althouse, Sandy K; Loehrer, Patrick J; Wakelee, Heather A.
Afiliação
  • Gubens MA; University of California, San Francisco, CA, United States. Electronic address: matthew.gubens@ucsf.edu.
  • Burns M; Indiana University, Indianapolis, IN, United States.
  • Perkins SM; Indiana University, Indianapolis, IN, United States.
  • Pedro-Salcedo MS; Stanford University, Stanford, CA, United States.
  • Althouse SK; Indiana University, Indianapolis, IN, United States.
  • Loehrer PJ; Indiana University, Indianapolis, IN, United States.
  • Wakelee HA; Stanford University, Stanford, CA, United States.
Lung Cancer ; 89(1): 57-60, 2015 Jul.
Article em En | MEDLINE | ID: mdl-26009269
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinazolinas / Timoma / Neoplasias do Timo / Carcinoma / Benzodioxóis / Antineoplásicos Tipo de estudo: Diagnostic_studies / Guideline Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinazolinas / Timoma / Neoplasias do Timo / Carcinoma / Benzodioxóis / Antineoplásicos Tipo de estudo: Diagnostic_studies / Guideline Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article